Credit Suisse’s Entrada Therapeutics TRDA Stock Holding History

Credit Suisse’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$227K	Buy	16,052 +196	+1%	+$2.77K	﹤0.01%	2884
2023 Q4	$239K	Sell	15,856 -630	-4%	-$9.33K	﹤0.01%	2952
2023 Q3	$260K	Sell	16,486 -670	-4%	-$10.6K	﹤0.01%	2973
2023 Q2	$260K	Buy	17,156 +4,757	+38%	+$65.5K	﹤0.01%	3046
2023 Q1	$180K	Buy	12,399 +3,588	+41%	+$47.9K	﹤0.01%	3136
2022 Q4	$119K	Buy	+8,811	New	+$154K	﹤0.01%	3302
2022 Q3	–	Sell	-6	Closed	–	–	4293
2022 Q2	$0	Buy	+6	New	+$46	﹤0.01%	4317

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Credit Suisse's TRDA Position: Q1 2024 in Review

Credit Suisse increased its Entrada Therapeutics (TRDA) stake by 1.2% in Q1 2024, buying an estimated $2.77K and bringing the position to 16,052 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #2884.

Credit Suisse first reported a position in TRDA in Q2 2022 and has held it in 7 quarters since. The position peaked at $260K in Q3 2023. 77 funds tracked by Wall St. Rank hold TRDA as of Q1 2024.

Credit Suisse held 16,052 shares of Entrada Therapeutics worth $227K as of Q1 2024.
Credit Suisse bought 196 Entrada Therapeutics shares in Q1 2024, an estimated $2.77K.
Entrada Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2884 holding.
Credit Suisse first reported a position in Entrada Therapeutics in Q2 2022 and has held it in 7 quarters since.
Credit Suisse's Entrada Therapeutics position peaked at $260K in Q3 2023.
77 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.